<DOC>
	<DOC>NCT00319592</DOC>
	<brief_summary>The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains after completion of vaccination course.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis, Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written informed consent obtained. Aged ≥18 to &lt;49 years. In good general health. Available for the study duration, including all planned followup visits. Females must have negative pregnancy test and be using adequate form of contraception Clinically significant abnormalities on laboratory and vital sign assessments. Anaphylaxis or other serious adverse reactions Administration of another vaccine within 30 days of study treatment period. Physical examination indicating any significant medical condition. Intention to travel out of the area prior to the study visit on Day 56. Seropositive to Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) or positive for Hepatitis B Surface Antigen. Pregnancy. Excessive alcohol consumption, drug abuse. Involvement in another clinical study within 60 days preceding the screening visit and during study treatment period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Japanese encephalitis</keyword>
	<keyword>ChimeriVax™-JE</keyword>
	<keyword>JE-VAX®</keyword>
</DOC>